Two Sigma Securities’s CRISPR Therapeutics CRSP Stock Holding History

Two Sigma Securities’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$564K	Buy	+10,341	New	+$545K	0.05%	529
2023 Q3	–	Sell	-6,864	Closed	-$354K	–	3017
2023 Q2	$385K	Buy	+6,864	New	+$389K	0.01%	1653
2023 Q1	–	Sell	-15,501	Closed	-$630K	–	2762
2022 Q4	$630K	Buy	15,501 +4,981	+47%	+$264K	0.02%	937
2022 Q3	$687K	Buy	10,520 +2,266	+27%	+$164K	0.02%	856
2022 Q2	$502K	Buy	+8,254	New	+$485K	0.02%	913
2022 Q1	–	Sell	-5,518	Closed	-$346K	–	2169
2021 Q4	$418K	Buy	+5,518	New	+$482K	0.02%	625
2021 Q3	–	Sell	-1,537	Closed	-$249K	–	1616
2021 Q2	$249K	Buy	+1,537	New	+$187K	0.01%	1132

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Securities's CRSP Position: Q2 2026 in Review

Two Sigma Securities opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 10,341 shares worth $564K. The stake represents 0.05% of the portfolio and ranks #529 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in CRSP as recently as Q2 2023.

Two Sigma Securities first reported a position in CRSP in Q2 2021 and has held it in 7 quarters since. The position peaked at $687K in Q3 2022. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Two Sigma Securities held 10,341 shares of CRISPR Therapeutics worth $564K as of Q2 2026.
CRISPR Therapeutics was a new Two Sigma Securities position in Q2 2026.
CRISPR Therapeutics made up 0.05% of Two Sigma Securities's portfolio in Q2 2026, its #529 holding.
Two Sigma Securities first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 7 quarters since.
Two Sigma Securities's CRISPR Therapeutics position peaked at $687K in Q3 2022.
523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.